Health Care • Biotechnology: Pharmaceutical Preparations
$540.00 ▲ +10.31
(+1.95%)
MKT CAP: $136.87B • VOL: 1.54M
52W L $403 52W H $564
VRTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $12.00B | $11.02B | $9.87B |
| YoY Revenue Growth % | +8.9% | +11.7% | — |
| Gross Profit | $10.35B | $9.49B | $4.34B |
| Gross Margin % | 86.2% | 86.1% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $4.17B | -$232.9M | $3.83B |
| Operating Margin % | 34.8% | -2.1% | 38.8% |
| Net Income (GAAP) | $3.95B | -$535.6M | $3.62B |
| EBITDA (Normalized) | $4.52B | $5.3M | $4.19B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $3.63B | -$492.6M | $3.54B |
| Capital Expenditures (CapEx) | $437.6M | $297.7M | $444.1M |
| Free Cash Flow (FCF) | $3.19B | -$790.3M | $3.09B |
| FCF Margin % | 26.6% | -7.2% | 31.3% |
| Return on Invested Capital (ROIC %) | 19.7% | -1.3% | 6.7% |
| Cash & Short-Term Equivalents | $5.08B | $4.57B | $8.28B |
| Total Debt (Short + Long Term) | $3.14B | $2.76B | $17.62B |
| Total Stockholders' Equity | $18.67B | $16.41B | $36.13B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VRTX.